The Future of Cervical Cancer Screening
Amelia Goldstein,Mallory Gersh,Gabriela Skovronsky,Chailee Moss
DOI: https://doi.org/10.2147/ijwh.s474571
2024-10-24
International Journal of Women s Health
Abstract:Amelia Goldstein, 1 Mallory Gersh, 2 Gabriela Skovronsky, 3 Chailee Moss 4 1 Duke University, Durham, NC, USA; 2 Wake Forest University, Winston-Salem, NC, USA; 3 University of Pennsylvania, Philadelphia, PA, USA; 4 George Washington University School of Medicine and Health Sciences, Washington, D.C., USA Correspondence: Amelia Goldstein, Clinical Research, Gynecologic Cancers Research Foundation, 25 W Houston St, Apt 3D, New York, NY, USA, Tel +1 410 599 3484, Email Purpose: Cervical cancer remains a significant health concern, particularly in developing countries, where it is a leading cause of cancer-related deaths among women. Innovative technologies have emerged to improve the efficiency, cost-effectiveness, and sensitivity of cervical cancer screening and treatment methods. This study aims to explore the various approaches for the detection and treatment of human papillomavirus (HPV), cervical dysplasia (CD), and cervical cancer, highlighting new technologies and updated screening strategies in developing areas. Patients and Methods: A comprehensive literature search was conducted using PubMed to identify relevant publications on the subject of cervical cancer screening and HPV detection. Results: HPV infection and cervical cancer continue to pose significant global health challenges. Emerging technologies such as rapid, low-cost HPV testing combined with high-resolution digital colposcopy and artificial intelligence interpretation hold promise for efficient and sensitive screening. Advancements in HPV vaccine distribution, high-risk HPV screening, DNA methylation assays, dual-stain cytology, lab-on-chip assays, and deep learning technologies offer new avenues for improved detection and risk stratification.Research and innovations in detection and treatment methods are crucial for reducing the burden of these diseases worldwide. Conclusion: Screening for HPV and CD plays a pivotal role in reducing the risk of cervical cancer-related mortality. The development of novel technologies, along with efforts to enhance global health equity and integrate cervical cancer prevention with HIV screening and treatment programs, represent critical steps toward achieving comprehensive cervical cancer screening on a global scale. Keywords: human papillomavirus, cervical automated visual evaluation, digital colposcope, HPV self-swab Cervical cancer is the fourth most common cancer globally and a leading cause of cancer deaths among women with an estimated 660,000 new cases and 350,000 deaths in 2022. 1 Low and middle-income countries have disproportionately high burdens of cancer, with around 90% of cervical cancer deaths in low-resource communities. 2 Over 95% of cervical cancer cases are attributed to infection by the human papillomavirus (HPV). 1 In developed countries, effective primary prevention (vaccination) and secondary prevention (regular screening programs) prevent most cervical cancer cases. A single cervical cancer screening in a woman's lifetime significantly reduces the risk of developing cervical cancer (a risk ratio of 0.65 when comparing single lifetime screening to no screening cohorts) 3 However, in low and middle-income areas, access to preventative measures is limited, delaying diagnosis of dysplastic lesions and cervical cancer until advanced stages. 4,5 Access to treatment and limited treatment modalities also result in higher mortality rates. 6 Further, in resource-limited countries increasing HIV prevalence and decreased funding for antiretroviral therapy, potentiates the pathogenesis of HPV. 7 Increased access to vaccines, genomic testing, and artificial intelligence technologies have the potential to vastly improve both primary and secondary prevention of cervical cancer. This article will describe these technologies which have the potential to dramatically lower cervical cancer mortality rates around the world. HPV is the most common viral infection of the reproductive tract, with most unvaccinated men and women contracting the virus at some point in their lives. 8 While most HPV infections do not cause symptoms and clear spontaneously within 1–2 years of infection, persistent infection with high-risk types may cause cervical cancer, among other diseases. 2 Around 5–10% of all women who contract HPV develop persistent infection. In the cervix, abnormal cell growth progresses over the course of months and years to premalignant glandular or squamous intraepithelial lesions, classified histopathologically as cervical intraepithelial neoplasia (CIN). The majority of low-grade CIN lesions regress spontaneously, whereas higher-grade lesions po -Abstract Truncated-
obstetrics & gynecology